Rituxan Offers Little Help for Sjogren's

(MedPage Today) -- Treatment for primary Sjogren's syndrome with the B-cell depleting antibody rituximab (Rituxan) failed to provide statistically significant improvements, despite the increasing evidence for B cells in the pathogenesis of this disorder, French researchers reported.
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news